AXON Axovant Sciences Ltd. Common Sh

12.14
+0.05  (0.41%)
Previous Close 12.09
Open 12.08
Price To book 7.20
Market Cap 1.20B
Shares 99,161,000
Volume 627,448
Short Ratio 18.98
Av. Daily Volume 276,032

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data due 4Q 2017
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Full study to be completed mid-2017. Phase 3 trial to be initiated 2H 2017.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data are due 3Q 2017.
Intepirdine - MINDSET
Alzheimer's disease

Latest News

  1. AXOVANT SCIENCES LTD. Financials
  2. Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?
  3. AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  4. Axovant reports 3Q loss
  5. Axovant reports 3Q loss
  6. Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016
  7. The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
  8. Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
  9. AXOVANT SCIENCES LTD. Files SEC form 8-K, Other Events
  10. Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients
  11. Axovant Rival's Alzheimer Drug Fails Study
  12. AXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
  13. Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital
  14. Axovant Sciences to Present at Upcoming Investor Conferences
  15. AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  16. Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference
  17. Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
  18. Coverage initiated on Axovant Sciences by Laidlaw
  19. Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer